Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
User discusses frustration with hair loss treatments and lack of progress. Emphasizes importance of measuring blood hormone levels to understand treatment effectiveness and side effects.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.
Inconsistent minoxidil use led to hair loss, prompting a plan to resume consistent application with derma stamping, red light therapy, and DHT blockers like clascoterone or RU58841. The user avoids finasteride and dutasteride due to past side effects.
Long-term use of dutasteride may impair semen volume and sperm motility, but these effects are often reversible after stopping the drug. Individual reactions vary, and more research is needed to understand the long-term impact on fertility.
Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.
The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.
The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.
The user has been using RU58841 for about 2 months without noticeable results or side effects and is unsure if this duration is sufficient to judge its effectiveness. Other users suggest continuing the treatment for at least 6 months and ensuring the product's authenticity.
A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.
A user questions if a topical compound with finasteride, dutasteride, minoxidil, retinoic acid, caffeine, and triamcinolone is excessive for hair loss treatment. Another user shares their experience using topical finasteride without issues and notes that alternating finasteride and dutasteride is common.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
The user experienced varying results with different hair loss treatments, including finasteride, minoxidil, RU58841, and dutasteride, with recent increased shedding after switching to a higher dose of dutasteride. They suspect the shedding is due to the dutasteride dose increase and question the effectiveness of dutasteride tablets from India.
A user's experiences with hair loss treatments, including finasteride and hair transplants, in relation to another person who has been publicly vocal about their own hair loss struggles. People have shared opinions on this other person's treatment choices and the results of their hair transplant.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.
The user has experienced hair loss stabilization with dutasteride and oral minoxidil but is considering adding RU58841 for potential regrowth. Another user advises that it may take up to 36 months for full results with dutasteride and warns of possible side effects with RU58841.
Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.
The user was using 1mg finasteride daily and oral minoxidil 2.5mg daily for two years, then added RU58841 to their routine two months ago and is asking for opinions on any changes in hair growth. They provided progress pictures without dermarolling and maintained consistent lighting for comparison.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.
The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.
The post is about a user experiencing a brutal shed after switching from taking dutasteride 3 days a week to taking it daily. The conclusion is that experiencing shedding when starting a new treatment is normal and varies from person to person.
The user experienced excessive bleeding during microneedling after consuming caffeine and THC, and is unsure if they should continue with the same routine. They are seeking advice on whether the bleeding is a cause for concern.